TG Therapeutics (TGTX) shares increased by 7.5%, closing at $46.62 during the last trading session, marking a significant rise supported by heavy trading volume. This surge follows the announcement of positive topline Phase 1 data for BRIUMVI, targeting myasthenia gravis (MG) patients, along with the initiation of a Phase 2 clinical trial for the same treatment.
For its upcoming quarterly report, TG Therapeutics is projected to earn $0.42 per share, a 147.1% increase year-over-year, while revenues are anticipated to reach $230.64 million, reflecting a 63.4% year-over-year growth. Notably, the consensus EPS estimate has escalated by 10.6% over the past month.
TG Therapeutics holds a Zacks Rank of #3 (Hold), while competitor Nurix Therapeutics, Inc. (NRIX) closed at $15.30, down 2.2% during the last session. Nurix’s EPS for the next report remains at -$0.73, a 40.4% decline from last year, giving it a Zacks Rank of #4 (Sell).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
